首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
【24h】

The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.

机译:静脉注射氟哌啶醇对危重患者QT间期离散度的影响:与QT间期延长的比较以评估尖锐湿疣的风险。

获取原文
获取原文并翻译 | 示例
       

摘要

The objective of this study was to determine the effect of intravenous haloperidol on QT interval dispersion in critically ill patients and to compare increases in QT interval dispersion and QTc intervals in patients who developed haloperidol-induced Torsades de Pointes versus those in patients who did not. This was a case-controlled study of 30 critically ill patients who received intravenous haloperidol for delusional agitation. Cases were patients (n = 6) who developed Torsades de Pointes during haloperidol therapy. Controls were patients (n = 24) who did not experience haloperidol-induced Torsades dePointes. QTc intervals were measured and QT interval dispersion was calculated. Haloperidol prolonged QTc interval compared to pretreatment values in Torsades de Pointes patients (606 +/- 61 ms vs. 501 +/- 44 ms, p = 0.007) by a greater magnitude than in patients who did not experience Torsades de Pointes (507 +/- 60 ms vs. 466 +/- 44, p = 0.01). Twelve-lead analysis revealed that QT interval dispersion increased in patients who experienced Torsades de Pointes (from 63 +/- 11 to 95 +/- 22 ms, p = 0.03) but not in those who did not (62 +/- 18 vs. 60 +/- 26 ms, p = 0.66). Analysis of precordial leads only showed no significant haloperidol-associated increases in QTinterval dispersion in eithergroup. The odds of developing haloperidol-induced Torsades de Pointes were highest in patients with QTc interval > 521 ms during haloperidol therapy(odds ratio = 12.1). It was concluded that intravenous haloperidol prolongs QTc intervals in critically ill patients. The degree of prolongation is greater in patients who experience Torsades de Pointes. QT interval dispersion may be increased in patients who develop haloperidol-induced Torsades de Pointes compared with those who do not. However, these effects are dependent on the method of measurement (12 leads vs. precordial leads). In addition, the odds of haloperidol-induced Torsades de Pointes are higherin patients with QTc intervalprolongation compared with increased QT interval dispersion. Therefore, QTc interval determination remains preferable to QT interval dispersion as a means assessment of risk for haloperidol-induced Torsades de Pointes.
机译:这项研究的目的是确定静脉内氟哌啶醇对危重患者QT间期离散度的影响,并比较氟哌啶醇诱发的Torsades de Pointes患者与未进行氟哌啶醇诱导的Torsades de Pointes患者的QT间期离散度和QTc间期的增加。这是一项病例对照研究,研究对象是30名危重患者,他们因静脉曲张而接受氟哌啶醇静脉注射。病例为在氟哌啶醇治疗期间出现尖角扭转型反扑的患者(n = 6)。对照组是未经历氟哌啶醇诱导的Torsades dePointes的患者(n = 24)。测量QTc间隔并计算QT间隔离散度。与未经历过扭转性尖锐湿疣的患者相比,氟哌啶醇相比于扭转性尖锐湿疣患者的治疗前值延长了QTc间隔(606 +/- 61 ms与501 +/- 44 ms,p = 0.007),幅度更大。 /-60毫秒与466 +/- 44,p = 0.01)。十二导联分析显示,经历过扭转性尖锐湿疣的患者的QT间期离散度增加(从63 +/- 11到95 +/- 22 ms,p = 0.03),但没有的患者则不然(62 +/- 18 vs 60 +/- 26毫秒,p = 0.66)。心前区导联的分析仅显示在两组中QTinterval离散度均未与氟哌啶醇相关的显着增加。氟哌啶醇治疗期间QTc间隔> 521 ms的患者出现氟哌啶醇诱发的Torsades de Pointes的几率最高(优势比= 12.1)。结论是危重患者静脉注射氟哌啶醇可延长QTc间隔。患有Torsades de Pointes的患者的延长程度更大。与没有氟哌啶醇诱发的扭转性扭转型室速的患者相比,QT间期离散度可能增加。但是,这些影响取决于测量方法(12根导联与心前导联)。此外,与QT间期离散度增加相比,QTc间期延长的患者使用氟哌啶醇引起的Torsades de Pointes的几率更高。因此,QTc区间测定仍优于QT区间弥散,以作为氟哌啶醇引起的Torsades de Pointes风险的手段评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号